Researchers from Yale have identified blood biomarkers that could noninvasively detect acute cellular rejection in heart transplant recipients, potentially replacing invasive heart biopsies. The study, published in Transplantation, analyzed immune cell changes in 12 patients, finding distinct biomarker patterns during rejection episodes.
“This is the first noninvasive method to differentiate types of heart rejection,” said co-author Dr. Sounok Sen. The team is now expanding research to 100 patients to validate these findings.
This breakthrough could transform transplant monitoring by reducing risks and discomfort associated with repeated biopsies.
Follow MEDWIRE.AI for cardiovascular transplantation innovations.
